Alnylam Pharmaceuticals | ALNY - Interest Income


Alnylam Pharmaceuticals reported $26.6M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.06M 277K Mar/2026
Agios Pharmaceuticals USD 10.8M 1.62M Mar/2026
Alnylam Pharmaceuticals USD 26.6M 32K Mar/2026
Arrowhead Research USD 16.93M 66K Jun/2026
BioCryst Pharmaceuticals USD -0.13 3.59M Dec/2024
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Incyte USD 38.12M 4.43M Jun/2026
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
Moderna USD 72M 2M Mar/2026
Regeneron Pharmaceuticals USD 183.3M 200K Jun/2026
Sanofi EUR 60M 54M Mar/2026
Sarepta Therapeutics USD 7M 1.74M Mar/2026
Takeda JPY 24.61B 213.76B Jun/2026
Tectonic Therapeutic USD 1.74M 217K Dec/2024
Ultragenyx Pharmaceutical USD 6M 512K Mar/2026
Vertex Pharmaceuticals USD 120.6M 5.8M Jun/2026
Xencor USD 5.46M 741K Mar/2026